Woodline Partners LP Sells 12,836 Shares of Ascendis Pharma A/S $ASND

Key Points

• Woodline Partners LP has reduced its stake in Ascendis Pharma A/S by 4.0%, selling 12,836 shares and retaining about 0.50% of the company valued at $47.5 million.
• For the most recent quarter, Ascendis Pharma reported a revenue of $216.28 million, surpassing the analyst estimates of $163.17 million, while posting an EPS of ($0.93).
• Investment analysts are optimistic about Ascendis Pharma's stock, with an average target price of $244.36 and 15 analysts rating the stock as a "Buy."

Woodline Partners LP cut its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 4.0% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 304,806 shares of the biotechnology company's stock after selling 12,836 shares during the period. Woodline Partners LP owned about 0.50% of Ascendis Pharma A/S worth $47,507,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ASND. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Ascendis Pharma A/S during the fourth quarter valued at $28,000. Brooklyn Investment Group increased its holdings in Ascendis Pharma A/S by 332.9% in the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 273 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Ascendis Pharma A/S in the fourth quarter valued at $174,000. Dearborn Partners LLC bought a new position in Ascendis Pharma A/S during the 1st quarter worth $203,000. Finally, New Wave Wealth Advisors LLC acquired a new position in Ascendis Pharma A/S during the 1st quarter worth about $222,000.

Ascendis Pharma A/S Stock Performance

Shares of ASND stock opened at $205.22 on Tuesday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $208.16. The stock has a 50 day simple moving average of $183.33 and a two-hundred day simple moving average of $168.42. The company has a market cap of $12.56 billion, a P/E ratio of -39.77 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to analyst estimates of $163.17 million. On average, research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. upped their price target on Ascendis Pharma A/S from $254.00 to $260.00 and gave the company an "overweight" rating in a research report on Tuesday, August 19th. Bank of America upped their target price on Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a "buy" rating in a report on Tuesday, September 2nd. Wells Fargo & Company reissued an "overweight" rating and set a $295.00 target price (up previously from $289.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Royal Bank Of Canada raised their price target on shares of Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $224.00 price objective (up from $215.00) on shares of Ascendis Pharma A/S in a research note on Friday, June 13th. Fifteen investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $244.36.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.